Profectus BioSciences Inc. Ebola Vaccine Contract with Department of Health & Human Services

Background

According to the “Schedule” portion of the contract/agreement:

There are currently no medical countermeasures available for the prophylaxis or treatment of infection with Ebola virus, a high priority agent for the Public Health Emergency medical Countermeasures Enterprise (PHEMCE) Implementation Plan.

An effective prophylactic vaccine would find application with medical personnel and close contacts during outbreaks in endemic areas of sub-Saharan Africa, with laboratory workers engaged in filovirus research, and with military and civilian personnel threatened by weaponized filoviruses. The ideal vaccine to meet both the outbreak and bio-weapon scenarios would rapidly confer protection with a single administration.

Continue scrolling for more...

Pre-clinical studies conducted by Profectus in collaboration with other laboratories have investigated an rVSVN4CT1 vectored vaccine encoding the surface glycoprotein (GP) of Zaire-EboV (rVSVN4CT1-Z- EbovGP). This rVSV vaccine is based on the bullet shaped Rhadovirus, vesicular stomatitis virus. The virus is a negative-strand, non-segmented RNA virus that has been modified to enable the delivery of immunogens. There is little pre-existing immunity in humans and the vectors can be engineered to express the surface glycoproteins of targeted viruses into the envelope of the VSV. The Profectus rVSV vaccine has demonstrated single dose protection in Guinea Pigs and NHPs against lethal challenge with Ebola and Marburg viruses. Profectus has shown safety of its rVSV platform in human studies of its rVSV-vectored HIV vaccine, which has completed 2 clinical trials in which safety, vaccine take, and immunogenicity across a range of doses was demonstrated.

This contract will support the advancement of the monovalent rVSVN4CT1 Ebola Zaire vaccine through preparation of an IND application for a Phase I clinical trial. These IND enabling activities include re-derivation of the recombinant vaccine under compliant conditions; a pre-IND meeting with the FDA to obtain feedback on the proposed path forward (specifically toxicology requirements); generation of immune serum from rabbits to neutralize vaccine during testing for adventitious agents; manufacture the monovalent vaccine under GMP conditions; toxicology testing and assays to support clinical evaluation.

The Advanced Research and Development effort will progress in specific stages that cover the base work segment and six (6) option work segments, as specified in this contract. The estimated period of performance for the base period is twelve (12) months. The work to be performed during the base segment represents a non-severable discrete work segment. Each of the option work segment represents further represents a non-severable discrete work segment. The work in the base segment and each option segment will be fully funded from funds that are available for obligation at the time of the initial award (Base segment) and at the time of the award of each option segment.

Document Archive

 Profectus BioSciences Inc. Ebola Vaccine Contract with Department of Health & Human Services [70 Pages, 2.5MB]

https://documents.theblackvault.com/documents/dhhs/2015-0077.pdf

Follow The Black Vault on Social Media:

This post was published on February 15, 2018 6:07 am

John Greenewald

Recent Posts

FOIA Appeal Adds New Dog Bite Details from Biden White House, Confirms Video Evidence Withheld

Newly obtained Secret Service records continue to shed light on the numerous biting incidents involving…

September 26, 2025

DoD Redacts Nearly All Records Explaining AARO’s Use of Law Enforcement Exemption for UAP Files

The Department of Defense (DoD) has released a set of heavily redacted emails in response…

September 25, 2025

Pentagon Denies Existence of “Yankee Blue” Memo Reported by Wall Street Journal

A Freedom of Information Act (FOIA) response has raised new questions about a widely circulated…

September 16, 2025

DoD Says Aerospace Firms Went “On the Record” About UAP — Then Refuses to Acknowledge Records Exist

In March 2024, the Department of Defense (DoD) published publicly its Report on the Historical…

September 6, 2025

NASA Cites FOIA Exemption to Withhold James Webb Briefing Content Despite Public Hearing

In September 2024, a Freedom of Information Act (FOIA) request was filed with NASA seeking…

September 3, 2025

FBI Files: Historical Figures & Groups

Background Welcome to the FBI Files on Historical Figures & Groups archive at The Black…

August 31, 2025